Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Verastem Discloses Research Results and Updated Clinical Plans

Published: Thursday, July 12, 2012
Last Updated: Thursday, July 12, 2012
Bookmark and Share
Company hosted its annual Research and Development Day where Robert Weinberg, Ph.D., Verastem co-founder and chair of the Scientific Advisory Board, gave a seminar on cancer stem cells.

Members of the Company’s management team provided updates to the product portfolio and advancements in the research and development pipeline.

“In order to generate a durable, clinical response in cancer we must design a treatment strategy that attacks the cancer stem cells, in addition to the other cancer cells, that comprise a tumor,” said Dr. Weinberg. “We founded Verastem in order to create therapies designed to specifically target cancer stem cells as these cells are resistant to standard cancer treatments. Verastem has made significant strides in the identification and development of small molecules that target this cancer stem cell population.”

Yesterday, Verastem announced the acquisition of an exclusive license to VS-6063 (formerly PF-04554878) from Pfizer. VS-6063 is a focal adhesion kinase (FAK) inhibitor that has completed a Phase 1 clinical study in advanced solid tumors. VS-6063 was well tolerated and showed signs of clinical activity in the study.

“A key component of Verastem’s IPO was to raise sufficient capital to rapidly progress the development of novel compounds targeting cancer stem cells,” said Christoph Westphal, M.D., Ph.D., Verastem Chairman and Chief Executive Officer. “With the in-license of VS-6063 from Pfizer, we have accelerated our clinical development plans for the FAK program by 12-18 months.”

“Our research has identified and prioritized key pathways necessary for the survival of cancer stem cells and yielded specific inhibitors to block these critical targets,” said Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research. “We are now poised to translate that research into multiple clinical trials over the next year with our cancer stem cell-targeted agents.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Study Identifies Novel Chemicals Targeting Cancer Stem Cells
Verastem, Inc., announced that researchers have published a study utilizing the cancer stem cell screening assay exclusively licensed to Verastem to identify novel chemicals that preferentially kill cancer stem cells.
Wednesday, November 28, 2012
Scientific News
The Mending Tissue - Cellular Instructions for Tissue Repair
NUS-led collaborative study identifies universal mechanism that explains how tissue shape regulates physiological processes such as wound healing and embryo development.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
iPS Cells Discover Drug Target for Muscle Disease
Researchers have designed a model that reprograms fibroblasts to the early stages of their differentiation into intact muscle cells in a step towards a therapeutic for Duchenne muscular dystrophy.
Engineered Hot Fat Implants Reduce Weight Gain
Scientists at UC Berkeley have developed a novel way to engineer the growth and expansion of energy-burning “good” fat, and then found that this fat helped reduce weight gain and lower blood glucose levels in mice.
Transplanted Stem Cells Can Benefit Retinal Disease Sufferers
Tests on animal models show that MSCs secrete growth factors that suppress causes of diabetic retinopathy and macular degeneration.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
Early Detection of Lung Cancer
The University of Manchester has signed a collaboration agreement with Abcodia to perform proteomics studies on a cohort of non-small cell lung cancer cases from the UKCTOCS biobank, with the aim of discovering new blood-based biomarkers for earlier detection of the disease.
Researchers Identify Drug Candidate for Skin, Hair Regeneration
Formerly undiscovered role of protein may lead to the development of new medications that stimulate hair and skin regeneration in trauma or burn victims.
Basis for New Treatment Options for a Fatal Leukemia in Children Revealed
Detailed molecular analyses allow new insights into the function of tumour cells and options for new treatments.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!